Literature DB >> 26870295

Radiation dose to the lymph drainage area in esophageal cancer with involved-field irradiation.

Wenbin Shen1, Hongmei Gao2, Shuchai Zhu1, Youmei Li1, Juan Li1, Zhikun Liu1, Jinwei Su1.   

Abstract

The aim of this study was to quantify the radiation dose to the corresponding lymph drainage area in esophageal cancer using three-dimensional conformal radiation therapy (3D-CRT) with involvED-field IRradiation (IFI) and to analyze associated factors. A retrospective analysis oF 81 patients with esophageal cancer was conducted. According to the location of the lesions, the lymph drainage area was delineated and the dosimetric parameters were calculated. The 1-, 3-, 5- and 8-year survival rates of the patients were 67.90, 33.33, 20.99 and 11.11%, respectively. Based on the dose-volume histogram in the treatment plan, we calculated the volume percentage of the planning target volume including clinically positive lymph nodes (PTV-N) receiving radiation doses of 30, 35, 40, 45 and 50 Gy (VPTV-N30-50). The median values of VPTV-N30-50 were 73, 70, 67, 64 and 58%, respectively. The prescribed dose size exhibited no correlation with VPTV-N30-35, but did exhibit a significant correlation with VPTV-N40-50; the radiation field was not correlated with VPTV-N30-45, but exhibited a significant correlation with VPTV-N50; The length of the lesion on esophageal barium meal X-ray and the PTV were significantly correlated with VPTV-N30-50. The analysis of variance revealed that the VPTV-NX value in the upper thoracic segment was higher compared with that in the middle and lower thoracic segments; VPTV-N30-35 values differed significantly according to the different locations of the lesions, whereas VPTV-N40-50 values exhibited no significant differences. The value of VPTV-NX exerted no significant effect on long-term patient survival. Therefore, the corresponding lymph drainage area of esophageal cancer IS subjected to a certain Radiation dose when patients undergo 3D-CRT with IFI, which may play a role in the prevention of regional nodal metastasis. However, this hypothesis requires confirmation by further clinical studies.

Entities:  

Keywords:  dosimetry; esophageal cancer; involved-field IRradiation; lymph drainage area; three-dimensional conformal radiation therapy

Year:  2015        PMID: 26870295      PMCID: PMC4726936          DOI: 10.3892/ol.2015.3952

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  14 in total

1.  Patterns of failure associated with involved field radiotherapy in patients with clinical stage I thoracic esophageal cancer.

Authors:  Yoshifumi Kawaguchi; Kinji Nishiyama; Ken Miyagi; Osamu Suzuki; Yuri Ito; Satoaki Nakamura
Journal:  Jpn J Clin Oncol       Date:  2011-06-10       Impact factor: 3.019

2.  Feasibility of involved-field conformal radiotherapy for cervical and upper-thoracic esophageal cancer.

Authors:  Jin-Bo Ma; Yi-Peng Song; Jin-Ming Yu; Wei Zhou; Er-Cheng Cheng; Xi-Qin Zhang; Li Kong
Journal:  Onkologie       Date:  2011-10-28

3.  Dose-response for subclinical disease--in response to Dr. Ben-Josef.

Authors:  H R Withers; L J Peters; J M Taylor
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-07-15       Impact factor: 7.038

4.  Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group.

Authors:  J S Cooper; M D Guo; A Herskovic; J S Macdonald; J A Martenson; M Al-Sarraf; R Byhardt; A H Russell; J J Beitler; S Spencer; S O Asbell; M V Graham; L L Leichman
Journal:  JAMA       Date:  1999-05-05       Impact factor: 56.272

5.  Proposed revision of the staging classification for esophageal cancer.

Authors:  R J Korst; V W Rusch; E Venkatraman; M S Bains; M E Burt; R J Downey; R J Ginsberg
Journal:  J Thorac Cardiovasc Surg       Date:  1998-03       Impact factor: 5.209

6.  INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy.

Authors:  Bruce D Minsky; Thomas F Pajak; Robert J Ginsberg; Thomas M Pisansky; James Martenson; Ritsuko Komaki; Gordon Okawara; Seth A Rosenthal; David P Kelsen
Journal:  J Clin Oncol       Date:  2002-03-01       Impact factor: 44.544

7.  Three-dimensional conformal radiation therapy for esophageal squamous cell carcinoma: is elective nodal irradiation necessary?

Authors:  Kuai-le Zhao; Jin-bo Ma; Guang Liu; Kai-liang Wu; Xue-hui Shi; Guo-liang Jiang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-12-11       Impact factor: 7.038

8.  Determination of the irradiation field for clinical T1-T3N0M0 thoracic/abdominal esophageal cancer based on the postoperative pathological results.

Authors:  Tatsuya Nakamura; Syunzo Hatooka; Takeshi Kodaira; Hiroyuki Tachibana; Natsuo Tomita; Rie Nakahara; Haruo Inokuchi; Nobutaka Mizoguchi; Akinori Takada; Masayuki Shinoda; Nobukazu Fuwa
Journal:  Jpn J Clin Oncol       Date:  2008-11-28       Impact factor: 3.019

9.  The pattern and prevalence of lymphatic spread in thoracic oesophageal squamous cell carcinoma.

Authors:  Junqiang Chen; Suoyan Liu; Jianji Pan; Xiongwei Zheng; Kunshou Zhu; Ji Zhu; Jinrong Xiao; Mingang Ying
Journal:  Eur J Cardiothorac Surg       Date:  2009-06-06       Impact factor: 4.191

10.  Study to determine adequate margins in radiotherapy planning for esophageal carcinoma by detailing patterns of recurrence after definitive chemoradiotherapy.

Authors:  Michael R Button; Carys A Morgan; Elizabeth S Croydon; S Ashley Roberts; Thomas D L Crosby
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-08-19       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.